ResearcherCapital Medical UniversityNo recent work listed

Yang Ge

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4855-6417; OpenAlex author ID A5085243153. Sources: OpenAlex.

Their work

Papers: 4
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 11

Papers, trials and grants by year

2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 1 paper

Papers 4

Inhibition of DCLK1 kinase reverses epithelial-mesenchymal transition and restores T-cell activity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2021.101317 ↗
Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer. Co-author DOI 10.1016/j.lfs.2019.117150 ↗
The Ras-ERK1/2 signaling pathway regulates H3K9ac through PCAF to promote the development of pancreatic cancer. Co-author DOI 10.1016/j.lfs.2020.117936 ↗
Short-term clinical outcomes of enteral nutrition versus parenteral nutrition after surgery for pancreatic cancer: a meta-analysis. Co-author DOI 10.21037/tcr.2019.07.47 ↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Guangyu An · 3 shared papers, 2019–2022 · strength 0.41
Rui Yan · 2 shared papers, 2020–2022 · strength 0.28
- Paper Inhibition of DCLK1 kinase reverses epithelial-mesenchymal transition and restores T-cell activity in pancreatic ductal… DOI 10.1016/j.tranon.2021.101317 ↗
- Paper Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer. DOI 10.1016/j.lfs.2019.117150 ↗
Xiaona Fan · 1 shared paper, 2022 · strength 0.16
- Paper Inhibition of DCLK1 kinase reverses epithelial-mesenchymal transition and restores T-cell activity in pancreatic ductal… DOI 10.1016/j.tranon.2021.101317 ↗
Yuanyuan Zhang · 1 shared paper, 2022 · strength 0.16
- Paper Inhibition of DCLK1 kinase reverses epithelial-mesenchymal transition and restores T-cell activity in pancreatic ductal… DOI 10.1016/j.tranon.2021.101317 ↗
Yi‐Kun Kang · 1 shared paper, 2019 · strength 0.14
- Paper Short-term clinical outcomes of enteral nutrition versus parenteral nutrition after surgery for pancreatic cancer: a me… DOI 10.21037/tcr.2019.07.47 ↗
Dong Li · 1 shared paper, 2019 · strength 0.14
- Paper Short-term clinical outcomes of enteral nutrition versus parenteral nutrition after surgery for pancreatic cancer: a me… DOI 10.21037/tcr.2019.07.47 ↗
Jing Ye · 1 shared paper, 2020 · strength 0.11
- Paper The Ras-ERK1/2 signaling pathway regulates H3K9ac through PCAF to promote the development of pancreatic cancer. DOI 10.1016/j.lfs.2020.117936 ↗
Mu Li · 1 shared paper, 2020 · strength 0.11
- Paper The Ras-ERK1/2 signaling pathway regulates H3K9ac through PCAF to promote the development of pancreatic cancer. DOI 10.1016/j.lfs.2020.117936 ↗
Yuhong Li · 1 shared paper, 2020 · strength 0.11
- Paper The Ras-ERK1/2 signaling pathway regulates H3K9ac through PCAF to promote the development of pancreatic cancer. DOI 10.1016/j.lfs.2020.117936 ↗
Shaowei Song · 1 shared paper, 2020 · strength 0.11
- Paper The Ras-ERK1/2 signaling pathway regulates H3K9ac through PCAF to promote the development of pancreatic cancer. DOI 10.1016/j.lfs.2020.117936 ↗
Xiaodong Tan · 1 shared paper, 2020 · strength 0.11
- Paper The Ras-ERK1/2 signaling pathway regulates H3K9ac through PCAF to promote the development of pancreatic cancer. DOI 10.1016/j.lfs.2020.117936 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.